Kite Pharma Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Kite Pharma (KITE) Tops Q2 EPS by 14c
August 10, 2015 4:09 PM EDTKite Pharma (NASDAQ: KITE) reported Q2 EPS of ($0.26), $0.14 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $2.51 million.
For earnings history and earnings-related data on Kite Pharma (KITE) click here.
... More